Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
REDWOOD CITY, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...
-
Investors who lost money in QURE after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.
-
Investors who lost money in DRVN after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.
-
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Alight (ALIT) To Contact Him Directly To Discuss Their Options If you purchased or...
-
Investors who lost money in APO after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.
-
Investors who lost money in RR after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.
-
NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Stellantis N.V. (“Stellantis” or the “Company”) (NYSE: STLA). Such investors are advised...
-
Investors who lost money in NAVN after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.
-
Ultragenyx allegedly misled investors about setrusumab’s potential Phase 3 study success in reducing fracture rates.
-
Investors who lost money in PYPL after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.